← Browse by Condition
Medical Condition

dlbcl

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2, Phase 2

ClinicalMetric tracks all active clinical trials for dlbcl sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — dlbcl Clinical Trials

How many clinical trials are currently recruiting for dlbcl?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for dlbcl, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for dlbcl?
dlbcl research spans Phase 1 (2 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a dlbcl clinical trial?
Eligibility criteria for dlbcl trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
3
Top Sponsors
Fudan University 1 trial
Institute of Hematology & Blood Diseases Hospital, China 1 trial
The First Affiliated Hospital with Nanjing Medical University 1 trial
Ruijin Hospital 1 trial

Recruiting Clinical Trials

NCT07070648
Recruiting

Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET

Enrollment
300 pts
Location
China
Sponsor
Fudan University
View Trial →
NCT07259070 Phase 1, Phase 2
Recruiting

Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma

Enrollment
20 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
View Trial →
NCT04432714 Phase 1, Phase 2
Recruiting

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

Enrollment
81 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →
NCT06701357 Phase 2
Recruiting

CR-CHOP+X in Previously Untreated DEL

Enrollment
49 pts
Location
China
Sponsor
Ruijin Hospital
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology